Awaiting development: Guidance and quality standards

Showing 61 to 70 of 321

Guidance and quality standards awaiting development
Title	Type
Delgocitinib for Chronic Hand Eczema [ID6688]	Technology appraisal guidance
Denecimig (Mim8) for preventing bleeding episodes in haemophilia A in people 1 year and over ID6400	Technology appraisal guidance
Denosumab biosimilar for Giant cell-rich tumours of bone or Skeletal events in bone malignancies ID12150	Technology appraisal guidance
Deucravacitinib for treating active psoriatic arthritis [TSID11981]	Technology appraisal guidance
Dexamethasone intracanalicular insert for treating inflammation and pain after cataract surgery [ID1154]	Technology appraisal guidance
Digital AI tools in histopathology (breast and prostate cancer)	Health technology evaluation
Digital tools and platforms to support the early detection and initial diagnosis of hearing loss	Health technology evaluation
Diverticular disease	Quality standard
Donanemab for reducing the risk of mild cognitive impairment in preclinical Alzheimer's disease [ID6675]	Technology appraisal guidance
Dorocubicel for treating haematological cancer when a suitable donor is unavailable for an allogeneic haematopoietic stem cell transplant [ID6521]	Technology appraisal guidance